We are thinking along the same lines. Not my field, but I am also curious what the ramifications are of just going after GM-CSF (given that IL6 on its own hasn't been effective so far). If the disease is RANTES driven as Dr. Patterson suggests, would this mean that you are only partially restoring immune system function by targeting GM-CSF (which may work better than nothing) as is the case with mavrilimumab for example?

https://www.thelancet.com/journals/lanrhe/art...3/fulltext

If you target GM-CSF will RANTES stay elevated? If that is the case, then you likely would have to deal with the ongoing recovery Dr. Patterson talked about in his TED talks right?

Ohm20?!?!?